Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma
Condition(s):Diffuse Large B Cell LymphomaLast Updated:December 20, 2023Recruiting
Hide Studies Not Open or Pending
Condition(s):Diffuse Large B Cell LymphomaLast Updated:December 20, 2023Recruiting
Condition(s):Relapsed/Refractory Diffuse Large B-cell LymphomaLast Updated:March 21, 2024Recruiting
Condition(s):Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type; Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell TypeLast Updated:February 15, 2024Active, not recruiting
Condition(s):Relapsed/Refractory Diffuse Large B-Cell LymphomaLast Updated:February 9, 2024Recruiting
Condition(s):Diffuse Large B-Cell LymphomaLast Updated:October 19, 2023Completed
Condition(s):Relapsed Diffuse Large B-cell Lymphoma; Refractory Diffuse Large B-cell LymphomaLast Updated:April 7, 2023Recruiting
Condition(s):Diffuse Large B Cell LymphomaLast Updated:August 31, 2022Recruiting
Condition(s):Diffuse Large B Cell Lymphoma Relapsed; Diffuse Large B Cell Lymphoma RefractoryLast Updated:February 5, 2019Completed
Condition(s):Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)Last Updated:September 11, 2023Completed
Condition(s):Diffuse Large B-cell LymphomaLast Updated:October 31, 2019Unknown status
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.